Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(3 years from now) | |
US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(5 years from now) | |
US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(12 years from now) | |
US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 6, 2025 |
Orphan Drug Exclusivity (ODE) | Mar 6, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 2024-03-06
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
16
United States
8
Japan
7
European Union
5
China
5
Korea, Republic of
4
Spain
4
Mexico
3
Denmark
3
Poland
3
Canada
3
Singapore
3
EA
3
Croatia
3
Cyprus
3
Peru
3
Israel
3
Portugal
3
Taiwan
3
Australia
3
Lithuania
3
Tunisia
3
Slovenia
3
Hungary
2
Philippines
2
Brazil
2
Morocco
2
Argentina
2
Norway
2
New Zealand
2
Chile
2
Ecuador
2
South Africa
1
IB
1
Hong Kong
1
Malaysia
1
Turkey
1
RS
1
Russia
1
Ukraine
1
ME
1
Guatemala
1
Jordan
1
Netherlands
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8415337 | RECORDATI RARE | Ibuprofen compositions and methods of making same |
Mar, 2032
(8 years from now) |
Drugs and Companies using IBUPROFEN LYSINE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(2 years from now) | |
US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
9
United States
4
European Union
3
United Kingdom
3
Norway
3
Korea, Republic of
3
Australia
2
Spain
2
Austria
2
Hong Kong
2
Malaysia
2
Denmark
2
Germany
2
China
2
Russia
2
Poland
2
Brazil
2
Canada
2
Argentina
2
Japan
2
New Zealand
2
Cyprus
2
Peru
2
Israel
2
Portugal
2
Taiwan
2
Mexico
2
Ecuador
2
South Africa
2
Slovenia
1
Iceland
1
Czech Republic
1
Morocco
1
Croatia
1
Belgium
1
Chile
1
Slovakia
1
Colombia
1
Luxembourg
1
Tunisia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(2 months from now) | |
US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(3 years from now) | |
US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
Market Authorisation Date: 15 December, 2014
Treatment: Method of treating acromegaly
Dosage: FOR SUSPENSION;INTRAMUSCULAR
11
United States
8
European Union
5
Korea, Republic of
4
Norway
4
Australia
3
Spain
3
Malaysia
3
Denmark
3
Poland
3
China
3
Brazil
3
Canada
3
Argentina
3
Japan
3
New Zealand
3
Peru
3
Israel
3
Portugal
3
Taiwan
3
Slovenia
3
Mexico
3
Ecuador
3
South Africa
3
United Kingdom
2
Hong Kong
2
Austria
2
Germany
2
Russia
2
Morocco
2
Cyprus
2
Luxembourg
2
Tunisia
2
Hungary
1
Uruguay
1
Panama
1
Dominican Republic
1
Iceland
1
Czech Republic
1
Ukraine
1
EA
1
ME
1
Nicaragua
1
Croatia
1
Honduras
1
San Marino
1
Belgium
1
Guatemala
1
Chile
1
El Salvador
1
Georgia
1
Cuba
1
Costa Rica
1
Slovakia
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic